16/10/2026 US FDA approved Roche’s satralizumab for TED US FDA approved UCB’s zilucoplan autoinjector adults with gMG Novartis halted a mid-stage Fablhalta study in lupus nephritis US FDA approved Roche’s satralizumab for TED (Ref) Roche’s Enspryng® (satralizumab; IL-6R inhibitor) received US FDA approval as the first and only at-home subcutaneous treatment for adults with thyroid eye disease (TED).The approval was based on Ph3, SatraGO-1 and SatraGO -2 studies. SatraGO-2 sho

17/07/2026 European Commission approved JASCAYD® as a treatment option for IPF and PPF in the EU Novartis received FDA traditional approval for Fabhalta® for the treatment of primary IgAN European Commission approved JASCAYD® as a treatment option for IPF and PPF in the EU (Ref) Boehringer Ingelheim announced that the European Commission had granted marketing authorization for JASCAYD® (nerandomilast; PDE4B inhibitor) for the treatment of adults with idiopathic pulmonary fibr